Kimer Med Limited
Kimer Med is a New Zealand-based biotechnology company founded in 2020, dedicated to ending the suffering caused by viral diseases through the development of safe and effective broad-spectrum antiviral therapeutics. Leveraging a proprietary platform for rapid antiviral drug design, Kimer Med targets the significant unmet need for treatments against the vast majority of human-infecting viruses, where 95% currently lack approved therapies. The company’s lead compound, VTose, has demonstrated efficacy against a wide range of viruses and is being advanced toward clinical trials. Kimer Med’s mission is to revolutionize antiviral treatment, providing rapid-response solutions for pandemic preparedness, neglected diseases, and global health security.
Industries
Nr. of Employees
small (1-50)
Products
Lead broad‑spectrum antiviral protein candidate
A recombinant protein‑based antiviral candidate designed to bind long viral dsRNA in infected cells and trigger apoptosis, intended as a therapeutic against multiple virus families.
Lead broad‑spectrum antiviral protein candidate
A recombinant protein‑based antiviral candidate designed to bind long viral dsRNA in infected cells and trigger apoptosis, intended as a therapeutic against multiple virus families.
Services
Project-based collaborative research programs to design, develop and test protein‑based broad‑spectrum antiviral candidates under contract for government agencies, research institutes and industry partners.
Coordination and management of in vitro screening and outsourced in vivo studies via independent laboratories to generate efficacy and toxicity data for candidate progression.
Negotiation and management of IP licences, out‑licensing deals and strategic partnerships to advance candidates through clinical development and into commercialization.
Advisory and operational support to pursue veterinary indications (pets and livestock) as an alternative or parallel route to market for antiviral candidates.
Project-based collaborative research programs to design, develop and test protein‑based broad‑spectrum antiviral candidates under contract for government agencies, research institutes and industry partners.
Coordination and management of in vitro screening and outsourced in vivo studies via independent laboratories to generate efficacy and toxicity data for candidate progression.
Negotiation and management of IP licences, out‑licensing deals and strategic partnerships to advance candidates through clinical development and into commercialization.
Advisory and operational support to pursue veterinary indications (pets and livestock) as an alternative or parallel route to market for antiviral candidates.
Expertise Areas
- Broad‑spectrum antiviral discovery
- Preclinical in vitro and in vivo evaluation
- Protein engineering and biologics formulation
- Virology assay development and mammalian cell culture
Key Technologies
- Recombinant protein therapeutics
- dsRNA‑targeting antiviral mechanism
- Apoptosis activation strategies
- Cell culture and CPE reduction assays
News & Updates
Kimer Med’s Business Development Manager, Dr Mike Schmidt, attended the 6th Asia Dengue Summit to learn about the international Dengue treatment market, meet collaborators, and advance plans for clinical trials in Asia. Kimer Med's VTose product was well received as a promising antiviral for Dengue.
Explores the complexities of Dengue fever, the challenges of developing treatments and vaccines for its four serotypes, and how Kimer Med’s approach targets a common viral process to overcome these barriers.
Discusses how Kimer Med’s antiviral pipeline aligns with Deloitte’s identified growth drivers in pharma, such as prioritizing unmet needs and novel mechanisms of action.
Clarifies Kimer Med’s mission, operations, and addresses misinformation, emphasizing their focus on broad-spectrum antivirals and not vaccines or mRNA technology.
Examines the burden of chronic viral diseases and how Kimer Med’s antivirals, which target viral dsRNA, may offer new treatment possibilities.
Discusses the links between viral infections and neurodegenerative diseases, and how Kimer Med’s antivirals could contribute to prevention or treatment.
Kimer Med’s Business Development Manager, Dr Mike Schmidt, attended the 6th Asia Dengue Summit to learn about the international Dengue treatment market, meet collaborators, and advance plans for clinical trials in Asia. Kimer Med's VTose product was well received as a promising antiviral for Dengue.
Explores the complexities of Dengue fever, the challenges of developing treatments and vaccines for its four serotypes, and how Kimer Med’s approach targets a common viral process to overcome these barriers.
Discusses how Kimer Med’s antiviral pipeline aligns with Deloitte’s identified growth drivers in pharma, such as prioritizing unmet needs and novel mechanisms of action.
Clarifies Kimer Med’s mission, operations, and addresses misinformation, emphasizing their focus on broad-spectrum antivirals and not vaccines or mRNA technology.
Examines the burden of chronic viral diseases and how Kimer Med’s antivirals, which target viral dsRNA, may offer new treatment possibilities.
Discusses the links between viral infections and neurodegenerative diseases, and how Kimer Med’s antivirals could contribute to prevention or treatment.